Eris Lifesciences Share Price Gains Over 8% on Q4 FY26 Earnings Result: Net Profit up 172.7% YoY

Written by: Team Angel OneUpdated on: 20 May 2026, 8:44 pm IST
Eris Lifesciences' total income rises 6.4% YoY to ₹758.79 crore in Mar 2026 quarter, with net profit surging 172.7% YoY.
Eris Lifesciences Share Price Gains
ShareShare on 1Share on 2Share on 3Share on 4Share on 5

Eris Lifesciences has announced its audited consolidated financial results for the quarter and year ending March 31, 2026.  

The company reported a notable increase in total income and net profit, reflecting strong financial performance. 

Eris Lifesciences Q4 FY26 Earnings Result 

In the quarter ending March 31, 2026, Eris Lifesciences achieved a total income of ₹758.79 crore, marking a 6.4% increase from ₹713.25 crore in the same quarter the previous year.  

However, this figure represents a 6.0% decline from the ₹807.47 crore recorded in the December 2025 quarter. 

The company's net profit (PAT) for the March 2026 quarter surged by 172.7% YoY to ₹279.10 crore, compared to ₹102.35 crore a year ago.  

This also indicates a significant 156.5% increase from ₹108.83 crore in the December 2025 quarter. 

Annual Financial Highlights for FY26 

For the financial year 2026, Eris Lifesciences reported a total income of ₹3,137.17 crore, reflecting a 7.7% increase from ₹2,912.00 crore in the previous year.  

The net profit for FY26 rose by 72.8% YoY to ₹647.51 crore, up from ₹374.67 crore in FY25. 

Read More: Zydus Lifesciences Share Price in Focus; Board Approves Buyback of Up to 95.65 Lakh Equity Shares at ₹1,150 Per Share! 

Interim Dividend Announcement 

Eris Lifesciences has declared an interim dividend of ₹7.21 per fully paid-up equity share of ₹1 each for the financial year 2026-2027.  

The record date for determining shareholder eligibility for the dividend is set for May 29, 2026, with payment to be made on or before June 19, 2026. 

Eris Lifesciences Share Price Performance 

As of May 20, 2026, at 2:59 PM, Eris Lifesciences share price on NSE was trading at ₹1,450.70 up by 8.57% from the previous closing price. 

Conclusion 

Eris Lifesciences has demonstrated robust financial growth in the March 2026 quarter and FY26, with significant increases in both total income and net profit. The declaration of an interim dividend further underscores the company's commitment to rewarding its shareholders. 

Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing. 

Published on: May 20, 2026, 3:12 PM IST

Team Angel One

Team Angel One is a group of experienced financial writers that deliver insightful articles on the stock market, IPO, economy, personal finance, commodities and related categories.

Know More

We're Live on WhatsApp! Join our channel for market insights & updates

Open Free Demat Account!

Join our 3.5 Cr+ happy customers

+91
Enjoy Zero Brokerage on Equity Delivery
4.4 Cr+DOWNLOADS
Enjoy ₹0 Account Opening Charges

Get the link to download the App

Get it on Google PlayDownload on the App Store
Open Free Demat Account!
Join our 3.5 Cr+ happy customers